You are here: Industry Insights > Kite

News List

Kite and Appia Bio to develop allogeneic cell therapies for blood cancer pharmaceutical-technology
August 09, 2021
Gilead unit Kite and Appia Bio have signed a partnership and licence agreement to research and develop off-the-shelf allogeneic cell treatments from hematopoietic stem cells (HSCs) for haematological cancers.
Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer americanpharmaceuticalreview
August 06, 2021
Kite, a Gilead Company, and Appia Bio, Inc. announced a collaboration and license agreement to research and develop HSC-derived cell therapies directed toward hematological malignancies.
BioNTech Acquires Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Maryland americanpharmaceuticalreview
August 05, 2021
BioNTech SE and Kite, a Gilead Company announced the closing of the acquisition of the solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility’s assets and leases in Gaithersburg, MD, from Kite.
BioNTech to Acquire Kite’s TCR Cell Therapy Platform and Mfg. Facility contractpharma
July 20, 2021
BioNTech SE and Kite, a Gilead Company, have entered a purchase agreement for BioNTech to acquire Kite’s solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, MD.
CAR T therapy achieves high remission rate in acute lymphoblastic leukaemia trial europeanpharmaceuticalreview
June 18, 2021
Trial data shows 71 percent of adult B cell acute lymphoblastic leukaemia patients receiving Tecartus® autologous anti-CD19-transduced CD3+ cell infusion achieved complete remission.
Kite and Shoreline Biosciences enter partnership to develop novel allogeneic cell therapies expresspharma
June 18, 2021
Kite, a Gilead Company and Shoreline Biosciences announced a strategic partnership to develop novel cell therapies across a variety of cancer targets.
Kite gets US FDA nod for Yescarta to treat relapsed or refractory follicular lymphoma expresspharma
March 08, 2021
Kite, a Gilead Company, announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two ...
Tecartus wins NICE recommendation for mantle cell lymphoma pharmatimes
January 20, 2021
The UK’s National Centre for Health and Care Excellence (NICE) has recommended Kite’s CAR-T therapy Tecartus (autologous anti-CD19 transduced CD3+ cells) for the treatment of certain adult patients with relapsed or refractory mantle cell lymphoma ...
Draper, Kite Ink Strategic Technology Pact contractpharma
December 16, 2020
Draper entered a multi-year strategic technology collaboration with Kite, a Gilead Company, to enhance Kite’s development of cell therapies using Draper’s engineering services and portfolio of cell bioprocessing technologies.
Kite, HiFiBiO Therapeutics partner to discover novel targets and antibodies against AML pharmaceutical-business-review
September 08, 2020
Kite, a Gilead Company and HiFiBiO Therapeutics announced the companies have entered into a two-year research collaboration and license agreement in acute myeloid leukemia (AML).

Previous page 1 2 Next page